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Aims Cardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventri-
cular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is
associated with hypertrophic cardiomyopathy (HCM).
Methods
and results
The study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocar-
diogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the
Spirito’s LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls,
patients with HCM exhibited higher (P, 0.001) plasma CT-1 levels. Significant correlations were found between CT-1
and maximal LV wall thickness (r ¼ 0.284, P ¼ 0.001) and the Spirito’s LVH score (r ¼ 0.287, P ¼ 0.006) in HCM
patients. In addition, the levels of CT-1 were higher (P ¼ 0.02) in patients with severe LVH (maximal LV wall thickness
≥30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness ,30 mm).
Conclusions These findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies
are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic
disease characterized by the development of left ventricular hyper-
trophy (LVH) in the absence of abnormal loading conditions that
could explain it.1– 4 It is one of the most common monogenic dis-
eases, affecting 1 in 500 adults in the general population.3,5 Early
diagnosis and risk stratification are mandatory in HCM because
this disease is the most frequent cause of sudden death in young
adults and sportsmen and women.3,6– 9 Multiple sudden death
risk factors have been identified, including the presence of family
history of sudden death, severe LVH (maximal LV wall thickness
≥30 mm), non-sustained ventricular tachycardia, unexplained
syncope, and abnormal blood pressure response on exer-
cise.1,6,8,10 –13 In addition, severe LVH is one of the main risk
factors for disease progression in HCM.1,4,12,13
Cardiotrophin-1 (CT-1) is a protein member of the IL-6 family
of cytokines that signals via leukaemia inhibitory factor receptor
gp130-dependent pathways and was originally characterized as a
factor that induces cardiomyocyte growth and survival.14,15
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Recent studies have confirmed an active role for CT-1 in promot-
ing myocardial structural changes, thereby participating in the pro-
gression of LV remodelling, which results in LV failure typical of
cardiac diseases such as hypertensive heart disease, aortic stenosis,
coronary artery disease, and dilated cardiomyopathy.16 In addition,
CT-1 plasma levels have been reported to be elevated in patients
with these conditions, and they are also correlated with the sever-
ity of the disease and heart failure.16 In particular, some recent
experimental and clinical observations suggest that CT-1 may con-
tribute to LV growth in hypertension. Experimental data show that
increased myocardial expression of CT-1 is associated with cardi-
omyocyte hypertrophy and development of LVH in spontaneously
hypertensive rats.17 Clinical data show that plasma CT-1 levels are
elevated in hypertensive patients, namely in those with LVH.18,19
and that an association exists between plasma CT-1 concentration
and LV mass index,18 as well as between the reduction of plasma
CT-1 and the regression of LVH in treated hypertensive patients.20
We have hypothesized that CT-1 may be involved in LVH in
HCM, therefore, our objectives were to analyse the potential
associations between plasma CT-1 levels and the parameters
assessing LVH in patients with HCM.
Methods
Subjects and clinical studies
All subjects gave written informed consent to participate in the study,
and the locally appointed Ethics Committee approved the research
protocol. The study conformed to the principles of the Helsinki
Declaration
The population consisted of 124 consecutive patients with HCM
recruited in the Complejo Hospitalario Universitario in A Corun˜a.
All patients were followed up in a specialized clinic and were period-
ically evaluated with a protocol that includes personal and familial ana-
mnesis, clinical evaluation, echocardiogram, Holter monitoring, and
exercise testing. Hypertrophic cardiomyopathy was diagnosed by the
presence of a non-dilated and hypertrophied left ventricle (LV
maximal wall thickness ≥15 mm) in the absence of another cardiac
or systemic disease capable of producing the hypertrophy observed,
or on the presence of unexplained electrocardiographic abnormalities
in relatives of patients with unequivocal disease.1,4 As hypertension has
a high prevalence in the general population, the presence of hyperten-
sion was not considered exclusion criteria for the diagnosis of HCM
when hypertension was mild and did not explain the severity of the
LVH.
A group of 29 subjects with the same age and sex distribution of the
study group recruited in the University Clinic in Pamplona were used
as control subjects for plasma CT-1 studies, comparing the CT-1 levels
of the 124 HCM patients with those of the 29 controls. The presence
of arterial hypertension, diabetes, coronary artery disease, aortic ste-
nosis, and HCM was excluded after complete clinical and cardiac
examination of these control subjects.
Echocardiographic study
Standard measurements, including Doppler parameters, were obtained
using an ultrasound system equipped with second harmonic imaging
(either Acuson-Siemens Sequoia C512, Mountain View, CA, USA, or
Sonos 5500, Philips Medical Systems, Andover, MA, USA). Echocardio-
graphic images were recorded on a magneto-optical disk. All measure-
ments were analysed offline by the same reader (L.M.) to minimize the
variability of the measurements, following the guidelines of the Amer-
ican Society of Echocardiography.21 Left ventricle wall thickness was
measured at 14 LV segments using paraesternal short views at
mitral, papillary, and apical levels, paraesternal long-axis and apical 4,
3, and 2 chambers views. At the mitral and papillary muscles level,
LV thickness was measured at anterior, anterior septum, posterior
septum, posterior, and lateral walls. At the apical level LV wall thick-
ness was measured at anterior, posterior, septal, and lateral walls.
The LV hypertrophy score proposed by Spirito and Maron12 was cal-
culated as the sum of the following measurements: maximal wall thick-
ness of anterior septum (either basal or mid-ventricular level), maximal
wall thickness of posterior septum (basal or mid-ventricular), maximal
wall thickness of the posterior wall (basal or mid-ventricular), and
maximal wall thickness of the anterolateral wall (basal or mid-
ventricular). LV ejection fraction (EF) was calculated with the
Simpson biplane method and systolic dysfunction was defined by the
presence of an EF, 50%. Left ventricle outflow tract velocities were
measured using continuous wave Doppler, and LV outflow tract gradi-
ents were calculated using the modified Bernoulli equation [LV outflow
tract gradient ¼ 4 (LV outflow tract velocity)2].
Holter monitoring
Two-channel ambulatory electrocardiogram monitoring was per-
formed in 118 patients. Non-sustained ventricular tachycardia was
defined as three or more consecutive ventricular beats at a rate of
≥120 beats/min, lasting for ,30 s.
Exercise testing
Symptom-limited exercise was performed on a treadmill using the
Bruce protocol. A physician was present during all studies to encou-
rage maximal exertion. Exercise capacity was defined as achieved
metabolic equivalents. Blood pressure was measured at rest, every
minute during exercise and for the first 5 min of recovery.
Blood pressure response to exercise was considered abnormal
when systolic blood pressure failed to increase by more than
25 mmHg from baseline, or when there was a decrease of more
than 10 mmHg from the maximum blood pressure during exercise.6
Determination of plasma cardiotrophin-1
Venous blood samples were taken at 08:30 h with all the subjects being
in fasting conditions. Plasma CT-1 was measured by an enzyme-linked
immunosorbent assay (ELISA) as previously reported.18 The inter-
assay and intra-assay coefficients of variation were 6.9 and 7.4%,
respectively. The lower limit of detection was 2.9 fmol CT-1/mL.
The upper limit of normality for plasma CT-1 values measured in
the control population was of 41 fmol/mL.
Statistic analysis
The statistical analysis was done using the statistical package SPSS 16.0
(SPSS, Inc., Chicago, IL, USA). Categorical variables are presented as
percentages and continuous variables are presented as mean
value+ standard deviation. Cardiotrophin-1 levels were compared
between two groups using the Student t-test for unpaired data once
normality was demonstrated (Shapiro–Wilk test); otherwise, a non-
parametric test (Mann–Whitney’s U test) was used. The correlation
between continuous variables was tested calculating Pearson corre-
lation coefficient and, when applicable, Spearman correlation coeffi-
cient. Partial correlation coefficients were calculated to exclude the
influence of potential confounding factors. Categorical variables were
analysed by the chi-square (x2) or Fisher exact test. For all the analyses
a bilateral P-value of ,0.05 was considered statistically significant.
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Results
Clinical characteristics
We studied 78 males (63%) and 46 females (37%) from 101 differ-
ent families. Age at diagnosis of HCM was 51+ 16 years (range
15–83) and at the first evaluation in our clinic it was 53+15
years (range 16–83). The main clinical and echocardiographic vari-
ables of the study group, including sudden death risk factors, are
summarized in Tables 1 and 2.
Echocardiographic characteristics
Mean maximal LV wall thickness was 21.3+6.1 mm (median 20,
range 9–42 mm, interquartile range 7). Table 2 summarizes the
wall thickness measurements in the different LV segments. Spirito’s
score was 66+ 17 mm (median 64, range 36–118 mm, intercuar-
tile range 17.5). Left atrial diameter was 45+ 9 mm (median 45,
range 25–96 mm, interquartile range 11). Thirty-three patients
(27%) had an LV outflow tract gradient ≥30 mmHg (obstructive
HCM) and 12 (10%) had severe obstruction with a gradient
≥90 mmHg. Mean EF was 70+12% (median 71, range 32–94%,
interquartile range 17) and systolic dysfunction was present in
six cases (5%).
Cardiotrophin-1 levels
As shown in Figure 1, plasma CT-1 was increased (P, 0.001) in
patients with HCM (136.28+72.01 fmol/mL) compared with
healthy controls (17.92+ 12.03 fmol/mL). The range of CT-1
values in patients was from 43 to 362 fmol/mL, with all patients
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Clinical and echocardiographic
characteristics of the study group
Variable Number (%)
Males/females 78 (63)/46 (37)
Family history of sudden death 20 (16)
Family history of HCM 51 (41)
Severe hypertrophy (≥30 mm) 13 (11)
Previous syncope 18 (15)
Non-sustained ventricular tachycardia 29 (23)
Abnormal blood pressure response on exercise
test
31 (25)
Previous angina 56 (45)
Obstructive (dynamic gradient ≥30 mmHg) 33 (27)
Systolic dysfunction 7 (6)
Previous atrial fibrillation 42 (34)
NYHA functional class
NYHA I 41 (33)
NYHA II 69 (56)
NYHA III 13 (11)
NYHA IV 1 (1)
Number of sudden death risk factorsa
0 risk factors 48 (38)
1 risk factors 51 (41)
2 risk factors 16 (13)
3 risk factors 8 (7)
4 risk factors 1 (1)
aSudden death risk factors included: family history of sudden death, severe
hypertrophy, previous syncope, abnormal blood pressure response on exercise
test, and non-sustained ventricular tachycardia on Holter monitoring.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Correlations between cardiotrophin-1 levels
and echocardiographic measurements
Variable Mean
value+ SD
Correlation
r
P-value
Basal anterior wall 15+5 0.329 0.007
Basal anterior septum 19+6 0.269 0.003
Basal posterior
septum
17+6 0.278 0.005
Basal posterior wall 11+2 0.229 0.011
Basal lateral wall 13+4 mm 0.371 0.001
Maximum basal wall
thickness
20+6 mm 0.250 0.005
Mid-ventricular
anterior wall
15+4 mm 0.159 0.217
Mid-ventricular
anterior septum
18+6 mm 0.168 0.107
Mid-ventricular
posterior septum
18+7 mm 0.216 0.056
Mid-ventricular
posterior wall
13+3 mm 0.286 0.009
Mid-ventricular lateral
wall
13+3 mm 0.292 0.017
Maximum
mid-ventricular
wall thickness
19+7 mm 0.241 0.018
Apical anterior wall 15+5 mm 0.223 0.054
Apical septal wall 14+5 mm 0.256 0.060
Apical posterior wall 13+4 mm 0.055 0.644
Apical lateral wall 14+5 mm 0.443 0.001
Maximum apical wall
thickness
16+5 mm 0.325 0.002
LV end-diastolic
diameter
44+6 mm 0.288 0.001
LV end-diastolic
diameter/body
surface area
24+4 mm/m2 0.310 <0.001
LV end-systolic
diameter
26+7 mm 0.184 0.043
LV end-systolic
diameter/body
surface area
14+4 mm/m2 0.219 0.015
LV ejection fraction 70+12% -0.028 0.760
Left atrial diameter 45+9 mm 0.205 0.023
Left atrial diameter/
body surface area
25+5 mm/m2 0.255 0.004
Aortic root diameter 34+4 mm 0.056 0.541
LV outflow tract
gradient
28+37 mmHg 0.029 0.754
LV, left ventricular.
Values in bold represent statistical significance.
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exhibiting values above the upper limit of normality of the control
population (mean + 1.96 SD). Plasma CT-1 levels were not influ-
enced by the presence of hypertension or antihypertensive
therapy.
Cardiotrophin-1 was higher (P ¼ 0.02) in patients with severe
LVH (maximal LV wall thickness ≥30 mm) than in patients with
mild o moderate LVH (maximal LV wall thickness ,30 mm;
Figure 2). Direct correlations were found between CT-1 and
maximal LV wall thickness (r ¼ 0.284, P ¼ 0.001; Figure 3A), and
Spirito’s score (r ¼ 0.287, P ¼ 0.006; Figure 3B). In addition, CT-1
was directly correlated with wall thickness in 9 out of the 14 LV
segments evaluated and with the maximal thickness at basal, mid-
ventricular, and apical levels, as well as with LV and left atrial
dimensions (Table 2). The associations of CT-1 with maximal LV
wall thickness and Spirito’s score remained significant when we
adjusted for the influence of these echocardiographic confounding
factors. No significant correlations were found between CT-1
levels and sex, presence of non-sustained ventricular tachycardia,
left ventricular outflow tract obstruction, previous syncope, abnor-
mal blood pressure response on exercise test, or previous atrial
fibrillation. Cardiotrophin-1 values were non-significantly higher
in patients with more sudden death risk factors, which could be
explained by the association of CT-1 values with the presence of
severe hypertrophy. The group of six patients with left ventricular
systolic dysfunction showed also higher CT-1 values than patients
without systolic dysfunction, but this difference was not statistically
significant (Table 3).
Discussion
The main findings of this study are as follows: (i) plasma CT-1
levels are increased in patients with HCM; and (ii) plasma CT-1
is associated with the severity of LVH in patients with HCM.
The observation that plasma CT-1 was abnormally increased in
patients with HCM expands previous findings in patients with
cardiac pathologies who present LVH due to pressure overload
such as hypertensive patients18,22 and patients with aortic steno-
sis.23 Since it has been reported that the human heart secretes
CT-1 via the coronary sinus into the peripheral circulation24 and
that plasma CT-1 is directly correlated with myocardial expression
of CT-1,25 increased plasma levels of CT-1 seen in patients with
HCM may reflect cardiac over-spilling of this cytokine. The ques-
tion arises about the factors determining the exaggerated cardiac
production of CT-1 in patients with HCM. Since the dynamic
outflow gradient represents a pressure load for the left ventricle
in patients with obstructive HCM, a mechanical factor may be
involved in up-regulation of CT-1 in some of these patients
(those with obstructive forms of the disease). In support of this
possibility, it has been reported that in patients with aortic valve
stenosis plasma CT-1 levels correlate with trans-valvular aortic
pressure gradients.23 Furthermore, ventricular stretch of Langen-
dorff perfused rat hearts resulted in significant release of CT-1.19
However, only 27% of our patients had LV obstruction, and no
difference was found in the CT-1 levels between patients with
and without obstruction. This means that CT-1 levels are more
likely associated with the presence of LVH than with the presence
of obstruction.
Our finding that plasma CT-1 correlates with parameters asses-
sing LV growth is in accordance with previous findings showing
similar correlations in hypertensive patients17 and in patients
with dilated cardiomyopathy,26 thus suggesting that this cytokine
may also contribute to the development of LVH in HCM. Further-
more, we also found that CT-1 levels are associated with the
severity of LVH, suggesting that up-regulation of this cytokine
may be involved in the progression of LVH in patients with
HCM. Moreover, our results also suggest a potential association
between CT-1 levels and the development of systolic dysfunction
in HCM, even thought the number of patients with systolic
Figure 1 Plasma concentration of cardiotrophin-1 (CT-1)
measured in 29 control subjects and in 124 patients with hyper-
trophic cardiomyopathy (HCM).
Figure 2 Plasma concentration of cardiotrophin-1 (CT-1) in
patients with hypertrophic cardiomyopathy classified according
to maximal left ventricular (LV) wall thickness.
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dysfunction included in this study was not sufficient to validate this
hypothesis. Up to 10% of the patients with HCM evolve to a
so-called burn-out phase of the disease, characterized by the
development of progressive wall thinning, LV dilatation and systolic
dysfunction.1,3,27 This evolution is more frequent in patients with
early expression of the disease and higher degrees of LVH. It is
Figure 3 (A) Direct correlation between plasma CT-1 and maximal left ventricular (LV) wall thickness (y ¼ 0.024x + 18.05) in patients with
hypertrophic cardiomyopathy. (B) Direct correlation between plasma cardiotrophin-1 (CT-1) and Spirito’s LV hypertrophy score
(y ¼ 0.067x + 56.91) in patients with HCM.
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Table 3 Relation between cardiotrophin-1 levels and categorical clinical variables
Variable Number (%) of patients with/
without the variable
Mean+ SD CT-1 levels in
patients with the variable
Mean+ SD CT-1 levels in
patients without the variable
P-value
Male sex 78 (63)/46 (37) 136+70 137+76 0.853
Non-sustained
ventricular tachycardia
29 (23)/95 (77) 153+83 129+68 0.119
Family history of HCM 51 (41)/73 (59) 129+66 141+76 0.357
Maximum wall thickness
≥30 mm
13 (10)/111 (90) 200+103 129+64 0.031
Obstruction (gradient
≥30 mmHg)
33 (27)/91 (73) 137+74 136+72 0.928
Systolic dysfunction 6 (5)/118 (95) 162+49 134+72 0.342
Previous syncope 18 (15)/106 (85) 133+56 137+75 0.817
Family history of sudden
death
20 (16)/104 (84) 124+68 139+73 0.398
Abnormal blood
pressures response
31 (25)/93 (75) 142+77 135+75 0.660
Previous angina 56 (45)/68 (55) 133+74 139+71 0.648
Atrial fibrillation ever 42 (34)/82 (66) 143+69 133+74 0.446
Number of sudden death
risk factors
0.07*
0 risk factors 48 (38) 123+65
1 risk factor 51 (41) 140+70
2 risk factors 16 (13) 178+83
3 or more risk factors 9 (8) 126+84
*P-value for linear association.
Values in bold represent statistical significance.
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associated with a higher incidence of ventricular arrhythmias, atrial
fibrillation, symptomatic heart failure and sudden death, and
requires therapeutic adjustments.1,7,27 It would be interesting to
evaluate in prospective studies whether CT-1 levels could be
early predictors of this evolution.
The stratification of the severity of LVH in patients with HCM is
highly relevant because morbidity, mortality, and sudden death risk
in these patients are associated with the severity of hypertro-
phy.6,8,12,13 However, the echocardiographic quantification of LV
mass has multiple limitations. In addition, the same wall thickness
or LV mass correspond to different severity of hypertrophy in
patients with different body surface area, sex or height and this
is not usually considered when analysing the prognostic significance
of LVH in individual patients. Even thought the associations found
between CT-1 levels and maximal wall thickness and Spirito’s
score were statistically significant, they presented modest corre-
lation coefficients (r ¼ 0.284 and r ¼ 0.287). This means that
CT-1 levels do not provide the same information as the other par-
ameters. The associations here reported between plasma CT-1
and maximal LV wall thickness and the Spirito’s LVH score, as
well as with the different LV segments and with the LV end-
diastolic diameter suggest that the plasma level of this cytokine
may be of potential usefulness as indicators of global left ventricu-
lar remodelling in patients with HCM.
Risk prediction is still an unsolved issue in patients with HCM. In
this regard, it has been reported that increased plasma CT-1
behaves as a prognostic marker of mortality in patients with
chronic HF.28 The potential mechanisms linking CT-1 with poor
prognosis are unclear, however, it has been reported that CT-1
induces cardiomyocyte dysfunction in reconstituted cardiac
tissue29 and an association has been found between plasma CT-1
and the impairment of systolic function in hypertensive patients
with stage congestive heart failure.22 Additionally, CT-1 may be
also involved in the development of myocardial fibrosis, an impor-
tant component of myocardial remodelling, since CT-1 induces
extracellular matrix protein synthesis in cardiac fibroblasts.30
Both the severity of LVH and the presence of systolic dysfunction
are associated with an increased risk of sudden death in HCM and
appear to be associated with CT-1 levels. Therefore, the possibility
that CT-1 may be related to prognosis in HCM deserves further
investigation.
In our study CT-1 levels did not show association with other
well-established sudden death risk factors, such as family history
of sudden death, presence of non-sustained ventricular tachycar-
dia, abnormal blood pressure response on exercise, or previous
syncope. The explanation for this lack of associations may be the
limited power of the study to detect modest associations.
Cardiotrophin-1 levels could also have a prognostic significance
independent of these factors; however, this aspect has not been
evaluated in the present study. Further work is necessary to
assess whether this cytokine may add prognostic information in
patients with HCM.
Some limitations of the current study must be acknowledged.
First of all, due to the limitations of echocardiography for an accu-
rate assessment of LV mass in HCM, magnetic resonance imaging
would have provided a better estimate of the LV mass, but it
was not available in a high number of cases. Second, there was
no one to one matching between healthy controls and patients
with HCM, and this imbalance precluded paired analysis. Third,
although it has been shown that the human heart secretes CT-1
via the coronary sinus into the peripheral circulation,24,25 given
the earlier evidence showing that CT-1 mRNA is expressed in
other organs,31 potential additional sources of circulating CT-1
can not be excluded in patients with HCM.
Conclusions
For the first time, we show that CT-1 plasma levels are increased
in patients with HCM. In addition, we report that plasma levels of
this cytokine are associated with the severity of LVH in patients
with HCM. Thus, the measurement of plasma CT-1 could
provide incremental value in the assessment of LVH severity in
these patients. Nevertheless, further large-scale prospective
studies are necessary to definitively validate this approach and to
evaluate the potential prognostic implications of CT-1 levels in
patients with HCM.
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